158 related articles for article (PubMed ID: 24264034)
1. Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%.
Schoenberger SD; Kim SJ; Sheng J; Calcutt MW
JAMA Ophthalmol; 2014 Feb; 132(2):150-4. PubMed ID: 24264034
[TBL] [Abstract][Full Text] [Related]
2. Reduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac, 0.45%, in patients with diabetic retinopathy.
Schoenberger SD; Kim SJ; Shah R; Sheng J; Cherney E
JAMA Ophthalmol; 2014 Jan; 132(1):32-7. PubMed ID: 24336915
[TBL] [Abstract][Full Text] [Related]
3. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%.
Heier JS; Awh CC; Busbee BG; Waterbury LD; Daniel P; Stoller GL; Cleary TS
Retina; 2009 Oct; 29(9):1310-3. PubMed ID: 19934822
[TBL] [Abstract][Full Text] [Related]
4. VITREOUS PROSTAGLANDIN E2 CHANGES AFTER TOPICAL ADMINISTRATION OF DICLOFENAC 0.1%, INDOMETHACIN 0.5%, NEPAFENAC 0.3%, AND BROMFENAC 0.09.
Pastore MR; De Giacinto C; Cirigliano G; D'Aloisio R; Addobbati R; Agostinis C; Radillo O; Di Martino G; Di Nicola M; Cecchini P; Tognetto D
Retina; 2020 Sep; 40(9):1838-1845. PubMed ID: 31800462
[TBL] [Abstract][Full Text] [Related]
5. REDUCTION OF VITREOUS PROSTAGLANDIN E2 LEVELS AFTER TOPICAL ADMINISTRATION OF INDOMETHACIN 0.5%, BROMFENAC 0.09%, AND NEPAFENAC 0.1.
Russo A; Morescalchi F; Vezzoli S; Bernini M; Turano R; Costagliola C; De Ferrari F; Semeraro F
Retina; 2016 Jun; 36(6):1227-31. PubMed ID: 26562569
[TBL] [Abstract][Full Text] [Related]
6. Vitreous and aqueous concentrations of brimonidine following topical application of brimonidine tartrate 0.1% ophthalmic solution in humans.
Takamura Y; Tomomatsu T; Matsumura T; Takihara Y; Kozai S; Arimura S; Yokota S; Inatani M
J Ocul Pharmacol Ther; 2015 Jun; 31(5):282-5. PubMed ID: 25918904
[TBL] [Abstract][Full Text] [Related]
7. Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification.
Bucci FA; Waterbury LD; Amico LM
Am J Ophthalmol; 2007 Jul; 144(1):146-7. PubMed ID: 17601444
[TBL] [Abstract][Full Text] [Related]
8. Topical ketorolac in vitreoretinal surgery: a prospective, randomized, placebo-controlled, double-masked trial.
Kim SJ; Lo WR; Hubbard GB; Srivastava SK; Denny JP; Martin DF; Yan J; Bergstrom CS; Cribbs BE; Schwent BJ; Aaberg TM
Arch Ophthalmol; 2008 Sep; 126(9):1203-8. PubMed ID: 18779478
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits.
Wang M; Liu W; Lu Q; Zeng H; Liu S; Yue Y; Cheng H; Liu Y; Xue M
Retina; 2012; 32(10):2158-64. PubMed ID: 23099451
[TBL] [Abstract][Full Text] [Related]
10. Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines.
Schoenberger SD; Kim SJ; Sheng J; Rezaei KA; Lalezary M; Cherney E
Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5906-11. PubMed ID: 22871833
[TBL] [Abstract][Full Text] [Related]
11. Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing.
Bucci FA; Waterbury LD
Adv Ther; 2009 Jun; 26(6):645-50. PubMed ID: 19568702
[TBL] [Abstract][Full Text] [Related]
12. Prostaglandin E
Acar U; Acar DE; Tanriverdi C; Acar M; Ozdemir O; Erikci A; Ornek F
Ocul Immunol Inflamm; 2017 Jun; 25(3):323-327. PubMed ID: 26765265
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation.
Barañano DE; Kim SJ; Edelhauser HF; Durairaj C; Kompella UB; Handa JT
Br J Ophthalmol; 2009 Oct; 93(10):1387-90. PubMed ID: 19628498
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels.
Bucci FA; Waterbury LD
J Cataract Refract Surg; 2008 Sep; 34(9):1509-12. PubMed ID: 18721711
[TBL] [Abstract][Full Text] [Related]
15. Effects of ketorolac tromethamine mouthrinse (0.1%) on crevicular fluid prostaglandin E2 concentrations in untreated chronic periodontitis.
Preshaw PM; Lauffart B; Brown P; Zak E; Heasman PA
J Periodontol; 1998 Jul; 69(7):777-83. PubMed ID: 9706855
[TBL] [Abstract][Full Text] [Related]
16. Penetration of topically applied diclofenac and ketorolac into the aqueous humour and subretinal fluid: randomized clinical trial.
Unlu N; Kocaoglan H; Sayin F; Hazirolan D; Demircan S; Basci N; Acar MA; Demir NM; Duman S
Can J Ophthalmol; 2010 Dec; 45(6):610-5. PubMed ID: 20935692
[TBL] [Abstract][Full Text] [Related]
17. Vitreous concentration of topically applied brimonidine tartrate 0.2%.
Kent AR; Nussdorf JD; David R; Tyson F; Small D; Fellows D
Ophthalmology; 2001 Apr; 108(4):784-7. PubMed ID: 11297498
[TBL] [Abstract][Full Text] [Related]
18. Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration.
Fiscella RG; Lai WW; Buerk B; Khan M; Rodvold KA; Pulido JS; Labib S; Shapiro MJ; Blair NP
Ophthalmology; 2004 Jun; 111(6):1191-5. PubMed ID: 15177970
[TBL] [Abstract][Full Text] [Related]
19. Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation.
Trattler W; McDonald M
Cornea; 2007 Jul; 26(6):665-9. PubMed ID: 17592313
[TBL] [Abstract][Full Text] [Related]
20. Topical ketorolac tromethamine in the reduction of adverse effects of laser in situ keratomileusist.
Kosrirukvongs P; Prabhasawat P; Srivannaboon S; Pornpanich K
J Med Assoc Thai; 2001 Jun; 84(6):804-10. PubMed ID: 11556458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
